.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the general public market.The Eli Lilly-partnered biotech plan to specify on the Nasdaq under the symbol "BIOA," depending on to files filed along with the Stocks and Exchange Percentage. The provider has actually not openly shared an anticipated financial volume for the offering.The clinical-stage company boasts lead prospect azelaprag, a by mouth provided small particle slated to get into phase 2 screening in combination along with semaglutide-- sold by Novo Nordisk under trademark name Wegovy for weight management-- in the 1st fifty percent of following year. Semaglutide is additionally sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is designed to integrate effectively with GLP-1 medications, increasing weight loss while maintaining muscular tissue mass. The investigational medication was discovered to be well-tolerated amongst 265 individuals across 8 phase 1 tests, depending on to BioAge.Recently, BioAge gathered the help of Lilly to operate a test incorporating azelaprag along with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetic issues as Mounjaro and Zepbound for weight management. The partners are actually currently conducting a period 2 test of azelaprag and tirzepatide, along with topline results anticipated in the third quarter of 2025.The biotech is actually additionally intending an insulin level of sensitivity proof-of-concept test examining azelaprag as a monotherapy in the 1st one-half of following year to assist potential evidence expansion. In addition, the business organizes to talk to the FDA for authorization in the 2nd fifty percent of 2025 to release human screening for an NLRP3 inhibitor targeting metabolic ailments and also neuroinflammation.BioAge's anticipated transfer to the public market follows a small uptick in organized biotech IPOs coming from Bicara Rehabs and Zenas Biopharma. Zooming out, the latest IPO garden is a "blended image," along with top quality business still debuting on everyone markets, just in minimized numbers, depending on to PitchBook.